NZ743625A - Human oncostatin m antibodies and methods of use - Google Patents

Human oncostatin m antibodies and methods of use

Info

Publication number
NZ743625A
NZ743625A NZ743625A NZ74362511A NZ743625A NZ 743625 A NZ743625 A NZ 743625A NZ 743625 A NZ743625 A NZ 743625A NZ 74362511 A NZ74362511 A NZ 74362511A NZ 743625 A NZ743625 A NZ 743625A
Authority
NZ
New Zealand
Prior art keywords
antibodies
methods
human oncostatin
oncostatin
human
Prior art date
Application number
NZ743625A
Inventor
Juan Carlos Almagro
Jose Pardinas
Johan Fransson
William Dubell
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of NZ743625A publication Critical patent/NZ743625A/en

Links

Abstract

An isolated antibody that specifically binds to Oncostatin M (OSM) and modulates the interaction between OSM and gp130.
NZ743625A 2010-10-13 2011-10-10 Human oncostatin m antibodies and methods of use NZ743625A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39268310P 2010-10-13 2010-10-13
NZ72608611 2011-10-10

Publications (1)

Publication Number Publication Date
NZ743625A true NZ743625A (en) 2022-11-25

Family

ID=84527765

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ743625A NZ743625A (en) 2010-10-13 2011-10-10 Human oncostatin m antibodies and methods of use

Country Status (1)

Country Link
NZ (1) NZ743625A (en)

Similar Documents

Publication Publication Date Title
ZA202206078B (en) Anti-cd3 antibodies and methods of use
EA201790664A1 (en) ANTIBODIES AGAINST MEZOTELINE AND IMMUNOCONJUGATES
MX2013011479A (en) Anti-fgfr4 antibodies and methods of use.
PH12015502565B1 (en) Anti-transferrin receptor antibodies and methods of use
MX346500B (en) Methods and compositions for neural disease immunotherapy.
MY178142A (en) Anti-phf-tau antibodies and their uses
NZ604510A (en) Dilutable biocidal compositions and methods of use
MX2014004022A (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE.
MX2013007168A (en) Anti-pcsk9 antibodies and methods of use.
UA117801C2 (en) Low affinity blood brain barrier receptor antibodies and uses therefor
MX2015013901A (en) Anti-il-4 antibodies and bispecific antibodies and uses thereof.
MX336682B (en) Antibodies against human csf-1r and uses thereof.
MX2013001473A (en) Antibodies against il-18r1 and uses thereof.
MX2014002053A (en) Anti-mcsp antibodies.
EP2566890A4 (en) Anti-pai-1 antibodies and methods of use thereof
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
MX2012011829A (en) Anti-polyubiquitin antibodies and methods of use.
MX2013002960A (en) Antibody compositions and methods of use.
MX2014014381A (en) Anti-theophylline antibodies and methods of use.
UA109148C2 (en) Compositions based on anti-vegfr-3 antibody
NZ743625A (en) Human oncostatin m antibodies and methods of use
MX2015004892A (en) Methods and compositions relating to anti-il-21 receptor antibodies.
GB201021909D0 (en) Multi-analyte microarrays using tag-specific antibodies and tag-anchored antibodies
MA43464A1 (en) Anti-cd3 antibodies and methods of use

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 9 YEARS UNTIL 10 OCT 2024 BY AJ PARK

Effective date: 20230419